Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced product candidate, apitegromab (SRK-015), a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, is currently in development for the treatment of spinal muscular atrophy, or SMA. We are currently evaluating apitegromab in our TOPAZ Phase 2 proof-of-concept trial in patients with later-onset (Type 2 and Type 3) SMA. Positive six-month interim analysis results were announced in October 2020 and top-line data for the full 12-month treatment period are anticipated in the second quarter of 2021. In addition, we are conducting our DRAGON Phase 1 proof-of-concept trial for SRK-181, a highly specific inhibitor of latent TGFβ1 activation, in patients with locally advanced and metastatic solid tumors. We believe SRK-181 has the potential to overcome resistance and meaningfully increase the number of patients who may benefit from checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 therapies.
Utilizing our proprietary platform, we are creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $103M
Founded date: 2012
Investors 2
Date | Name | Website |
17.07.2021 | ARCH Ventu... | archventur... |
- | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 3
Date | Series | Amount | Investors | Deal News |
03.01.2018 | Series C | $47M | ARCH Ventu... | citybizlis... |
04.01.2016 | Series B | $36M | - | finsmes.co... |
15.09.2014 | Series A | $20M | - | medcitynew... |
Mentions in press and media 15
Date | Title | Description | Source |
29.09.2021 | Scholar Rock : Announces Issuance of U.S. Patent Protecting ... | CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused o... | marketscre... |
14.06.2021 | SCHOLAR ROCK HOLDING CORPORATION Scholar Rock : Presents TO... | CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused o... | marketscre... |
04.01.2018 | Term Sheet — Thursday, January 4 | TAKING A HIATUS Good morning, Term Sheet readers. Paid Content You can't secure what you can't see... | fortune.co... |
03.01.2018 | ARCH Venture Joins $47 Million Series C For Scholar Rock | SRK-015 to move into clinical development for Spinal Muscular Atrophy (SMA) in first half of 2018; d... | citybizlis... |
03.01.2018 | Scholar Rock Announces $47 Million Series C Financing | SRK-015 to move into clinical development for Spinal Muscular Atrophy (SMA) in first half of 2018; d... | citybizlis... |
03.01.2018 | Scholar Rock Raises $47M in Series C Financing | Scholar Rock, a Cambridge, Mass.-based biotechnology company focused on discovering and developing d... | finsmes.co... |
03.01.2018 | Scholar Rock Announces $47M in Series C | CAMBRIDGE, MA, Scholar Rock announced the closing of a $47 million Series C financing led by new i... | vcnewsdail... |
03.01.2018 | A better approach to growth factors? Scholar Rock raise... | Scholar Rock, a biotech based of out Cambridge, MA, just got a $47 million infusion of cash to ... | endpts.com... |
04.01.2016 | Scholar Rock Nets $36M Series B Financing | CAMBRIDGE, MA, Biotechnology company announced a $36 million Series B financing. >> Click h... | vcnewsdail... |
04.01.2016 | Scholar Rock Raises $36M in Series B Financing | Scholar Rock, a Cambridge, MA-based biotechnology company focused on discovering and developing drug... | finsmes.co... |
Show more